 "Dr Reddy's Lab touches new lifetime high")
Shares of Dr Reddy’s Laboratories have moved higher by 3.2% to Rs 4,327 on the National Stock Exchange (NSE) after the company said it will expand in Europe and grow its proprietary products business over the next two years.
The company also says it is looking at growth through mergers and acquisitions. CLICK HERE TO READ FULL REPORT.
Meanwhile, the company today announced that it has entered into a strategic collaboration with Amgen – one of the world’s leading independent biotechnology companies - to market and distribute three Amgen medicines in India in the areas of oncology and cardiology.
Under the terms of the collaboration, Dr Reddy’s shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfizomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India, Dr Reddy’s Laboratories said in a press release.
Meanwhile, since July 29, the stock has outperformed the market by surging 17% from Rs 3,712 after reported a better than expected 13.7% year-on-year jump in consolidated net profit at Rs 626 crore in the June quarter, on the back of improved gross profit margins. The CNX Nifty gained 2.4% during the same period.
The company also says it is looking at growth through mergers and acquisitions. CLICK HERE TO READ FULL REPORT.
Meanwhile, the company today announced that it has entered into a strategic collaboration with Amgen – one of the world’s leading independent biotechnology companies - to market and distribute three Amgen medicines in India in the areas of oncology and cardiology.
Under the terms of the collaboration, Dr Reddy’s shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfizomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India, Dr Reddy’s Laboratories said in a press release.
Meanwhile, since July 29, the stock has outperformed the market by surging 17% from Rs 3,712 after reported a better than expected 13.7% year-on-year jump in consolidated net profit at Rs 626 crore in the June quarter, on the back of improved gross profit margins. The CNX Nifty gained 2.4% during the same period.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%